Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AACR 2021 | Current activites at Transgene

Kaidre Bendjama • 15 Apr 2021
AACR 2021
General

Kaidre Bendjama, Transgene, Strasborg, France, outlines the current activities of Transgene, a biotechnology company that designs and develops innovative immunotherapies, including personalized therapeutic vaccines and multifunctional oncolytic viruses. This interview took place at the virtual American Association for Cancer Research (AACR) Annual Meeting 2021.

Disclosures

Kaidre Bendjama is a full-time employee of Transgene SA.

More from Kaidre Bendjama

2:25
Using oncolytic viruses in solid tumors
Kaidre Bendjama • 15 Apr 2021
4:35
TG6002, an oncolytic virus induces expression of a pro-drug activating enzyme in advanced GI cancers
Kaidre Bendjama • 15 Apr 2021

Related Videos

1:56
Phase I trial of trastuzumab deruxtecan and neratinib in HER2-altered tumors
Haeseong Park • 8 Apr 2024
2:45
Remaining challenges in treating solid tumors with CAR-Treg therapy
Leonardo Ferreira • 8 Apr 2024
2:01
Engineering chimeric antigen receptor regulatory T cells for treating cancer
Leonardo Ferreira • 8 Apr 2024
0:59
What challenges are there in using CAR-T cells for solid tumors?
Leonardo Ferreira • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals